ISO 14155:2019 … Changes to Expect

by | Sep 13, 2019 | 510k, FDA, ISO, Medical Devices, Quality Systems, Regulatory

ISO 14155 [Clinical investigation of medical devices for human subjects – Good clinical practice], as the name suggests, addresses good clinical practices for all pre- and post-market clinical investigations that determine the safety and performance of medical devices. The final publication of the 3rd edition of ISO 14155 is coming soon in 2019, with some key changes that manufacturers should consider.

Some key changes that will build upon the current edition of 14155:2011 is the inclusion of more vigorous risk management requirements across the whole lifecycle of clinical investigations. ISO 14155:2019 will closely tie risk management practices from ISO 14971 into all required clinical investigation processes. Some other notable changes to the standard in the upcoming 3rd edition include:

  • A summary section of GCP principles
  • Inclusion of guidance for clinical quality management
  • Inclusion of risk-based monitoring
  • Guidance on study design and statistical considerations
  • Increased clarity on how to apply the standard to different clinical development stages
  • Guidance on clinical investigation audits
  • The requirement of specific medical expertise in clinical investigation planning1

Currently, the revision is in the approval phase and being identified as ISO/FDIS 14155 because it is the final draft before publication, which is when it will start being identified as ISO 14155:2019. At this point the revision has been voted on by industry, technical, and regulatory experts and the next steps are approval for publication, which will turn the draft into an international standard.2

Have any questions about clinical investigations for your medical device or need help complying with international standards? Contact us at 248-987-4497 or email:

1ISO (n.d.) ISO/DIS 14155(en) retrieved on 09/10/2019 from

2ISO (n.d.) ISO/FDIS 14155 General Information retrieved on 09/10/2019 from

Emma International

Emma International

More Resources

FDA Adverse Event Reporting 

FDA Adverse Event Reporting 

When reporting an Adverse Event to the Food and Drug Administration (FDA) the best method is to utilize the FDA Adverse Event Reporting System (FAERS). FAERS is a database that contains adverse event reports, product quality complaints that led to an adverse event, and medication error reports1. All FAERS reports are easily accessible to the public. 
De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.

Ready to learn more about working with us?

Pin It on Pinterest

Share This